Correction: Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese patients with moderate to very severe aplastic anemia: a case series

Affiliations

¹ Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-Shi, Tochigi-Ken, 329-0498, Japan. ycanda-tky@umin.ac.jp.
² Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
³ Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
⁴ Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
⁵ Pfizer Inc, New York, NY, USA.
⁶ Pfizer R&D Japan, Tokyo, Japan.

Published Erratum

Yoshinobu Kanda et al. Int J Hematol. 2023 Mar.

. 2023 Mar;117(3):469.

doi: 10.1007/s12185-023-03543-9.

¹ Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-Shi, Tochigi-Ken, 329-0498, Japan. ycanda-tky@umin.ac.jp.
² Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
³ Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
⁴ Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
⁵ Pfizer Inc, New York, NY, USA.
⁶ Pfizer R&D Japan, Tokyo, Japan.

No abstract available

Erratum for

Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese patients with moderate to very severe aplastic anemia: a case series.
Kanda Y, Mori T, Narita A, Wolter KD, Yoshimatsu H, Nishimura K. Kanda Y, et al. Int J Hematol. 2023 Jan;117(1):37-43. doi: 10.1007/s12185-022-03496-5. Epub 2022 Nov 28. Int J Hematol. 2023. PMID: 36441357 Free PMC article.